ReviewNeurobiology of disease2010
Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach.
Review in Neurobiology of disease, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 71 citations in OpenAlex.
- Molecular characterization of the circadian clock in patients with Parkinson's disease-CLOCK4PD Study protocol.PloS one · 2024Article
- DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.Nature aging · 2023Article
- Noninvasive Neuromodulation in Parkinson's Disease: Insights from Animal Models.Journal of clinical medicine · 2023Review
- MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases.International journal of molecular sciences · 2022Review
- Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies.Biomolecules · 2020Article
- miRNAs as Biomarkers in Disease: Latest Findings Regarding Their Role in Diagnosis and Prognosis.Cells · 2020Review
- Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.BMC neurology · 2020Article
- Proteomics in Human Parkinson's Disease: Present Scenario and Future Directions.Cellular and molecular neurobiology · 2019Review
- Repetitive transcranial magnetic stimulation protects mice against 6-OHDA-induced Parkinson's disease symptoms by regulating brain amyloid βMolecular and cellular biochemistry · 2019Article
- N-Propargyl Caffeamide (PACA) Ameliorates Dopaminergic Neuronal Loss and Motor Dysfunctions in MPTP Mouse Model of Parkinson's Disease and in MPPMolecular neurobiology · 2018Article
- Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson's Disease: A Critical Review.Journal of neurogastroenterology and motility · 2018Review
- microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.International journal of molecular sciences · 2017Review
- Transcription Factors: Potential Cell Death Markers in Parkinson's Disease.Neuroscience bulletin · 2017Review
- Parkinson's Disease: Assay of Phosphorylated α-Synuclein in Skin Biopsy for Early Diagnosis and Association with Melanoma.Brain sciences · 2016Article
- Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins.Expert review of proteomics · 2016Review
- Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.Oncotarget · 2015Article
- Biomarkers of Parkinson's disease: present and future.Metabolism: clinical and experimental · 2015Review
- The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis.Parkinson's disease · 2015Review
- Proteomic analyses of CSF aimed at biomarker development for pediatric brain tumors.Journal of neuro-oncology · 2014Review
- Does restraining nitric oxide biosynthesis rescue from toxins-induced parkinsonism and sporadic Parkinson's disease?Molecular neurobiology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inaccuracy of the early diagnosis of Parkinson's disease (PD) has been a major incentive for studies aimed at the identification of biomarkers. Brain-derived cerebrospinal fluid (CSF) proteins are potential biomarkers considering the major role that proteins play in PD pathogenesis. In this review, we discuss the current hypotheses about the pathogenesis of PD and identify the most promising candidate biomarkers among the CSF proteins studied so far. The list of potential markers includes proteins involved in various pathogenetic processes, such as oxidative stress and protein aggregation. This list will undoubtedly grow in the near future by application of CSF proteomics and subsequent validation of identified proteins. Probably a single biomarker will not suffice to reach high sensitivity and specificity, because PD is pathogenetically heterogeneous and shares etiological factors with other neurodegenerative diseases. Furthermore, identified candidate biomarkers will have to be thoroughly validated before they can be implemented as diagnostic aids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.